Johnson & Johnson JNJ earnings Q3 2020

Earnings


Alex Gorsky, Chairman and CEO of Johnson & Johnson, rings the opening bell to celebrate the 75th anniversary of his company’s listing at the New York Stock Exchange, September 17, 2019.

Brendan McDermid | Reuters

Johnson & Johnson on Tuesday reported third-quarter earnings and revenue that beat Wall Street’s expectations, led by higher sales in its medical-device unit and higher demand for some of its drugs.

J&J reported an adjusted earnings of $2.20 per share, higher than the $1.98 per share projected by analysts surveyed by Refinitiv. The company generated $21.08 billion in revenue, higher than the $20.2 billion expected and up from $20.72 last year.

The company also raised its full-year guidance, expecting adjusted earnings of $7.95 to $8.05 from per share from $7.75 to $7.95 per share. It also raised its sales forecast to a range of $82 billion to $82.8 billion from $79.9 billion to $81.4 billion.

J&J’s pharmaceutical business, which is working on a coronavirus vaccine, generated $11.4 billion in revenue, a 5% year-over-year increase. The vaccine’s late-stage trial was just paused after one of its participants reported an “adverse event,” Chief Financial Officer Joseph Wolk said in an interview on CNBC’s “Squawk Box” on Tuesday.

J&J’s share price fell1.5% on Tuesday, to $149.55 per share.

The company’s consumer unit, which makes products such as Listerine, generated $3.5 billion in revenue, up 1.3% from a year earlier. Its medical device unit generated $6.1 billion, a 1.7% increase.

“Our world-class R&D team is working tirelessly to advance the Phase 3 trials of our COVID- 19 vaccine and to uphold the highest standards of transparency, safety and efficacy; while other dedicated teams provide ongoing support to hospitals and patients as they return to sites of care, and ensure patients and consumers have the medicines and products they need,” J&J CEO Alex Gorsky said in a press release.

J&J began its phase three trial testing of its potential coronavirus vaccine last month, becoming the fourth drugmaker backed by the Trump administration’s Covid-19 vaccine program Operation Warp Speed to enter late-stage testing.

J&J confirmed to STAT News on Monday that the 60,000-patient clinical trial had been temporarily paused due to an unexplained illness in a study participant.

AstraZeneca announced on Sept. 8 that its trial had been put on hold due to an unexplained illness in a patient in the United Kingdom. The trial has since resumed in the U.K. and other countries, but is still on hold in the United States.



Source link

Products You May Like

Articles You May Like

Chinese to shun U.S. brands: AlixPartners
Meet the advisor ranked No. 1 by CNBC two years in a row
General Electric (GE) earnings Q3 2020 beat expectations
You don’t have to be rich to hire a financial advisor
Higher taxes could be around the corner. How the wealthy might prepare

Leave a Reply

Your email address will not be published. Required fields are marked *